Search
for
Sort by
Research 661–690 of 1000+
- Development of MALDI-TOF-MS and MALDI-MSI methods for hair analysis and evaluation of cosmetic treatments
- Dermatite atópica em uma cadela: Caso clínico
- The evaluation of IL-4 VNTR intron 3 and TNF-α (rs1799964) gene polymorphisms in Egyptian patients with alopecia areata: a case–control study
- 061 Selective inhibition of tyrosine kinase 2 prevents and restores interleukin-12-induced hair follicle immune privilege collapse: a novel approach to alopecia areata therapy?
- 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
- Correlation between increased total serum IgE levels and clinical features in alopecia areata patients
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Antroquinonol Exerts Immunosuppressive Effect on CD8<sup>+</sup> T Cell Proliferation and Activation to Resist Depigmentation Induced by H<sub>2</sub>O<sub>2</sub>
- DcR3 reprograms macrophage plasticity to promote wound healing and hair regeneration
- 436 Allergic contact dermatitis stimulates hair follicle stem cells via macrophage-mediated regulation
- LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- Lrig1-expression confers suppressive function to CD4+ cells and is essential for averting autoimmunity via the Smad2/3/Foxp3 axis
- Biomarkers in alopecia Areata: A systematic review and meta-analysis.
- The Role of Vitamin D in Autoimmune Thyroid Diseases: From Immunomodulation to Clinical Implications
- The expanding impact of T-regs in the skin
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- 649 Gut microbiota plays a role in the development of alopecia areata
- ILC3s as central regulators of mucosal homeostasis and disease pathogenesis (Review)
- 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse
- Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
- ISIDLB1777 - A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- Interleukin-10-deficient Mice Are Less Susceptible to the Induction of Alopecia Areata
- Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata
- Immune therapies for alopecia areata: evidence and new perspectives
- Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
- A bibliometric analysis of T cell and atherosclerosis
- PD-1+CXCR5−CD4+T cells are correlated with the severity of systemic lupus erythematosus
- Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
- Efficacy and safety of methotrexate in alopecia areata
- Probiotics in Dermatology: An Evidence-based Approach